Baricitinib Effective for Polymyalgia Rheumatica Without Steroids
January 23, 2025
A small, randomized, double-blind, placebo-controlled study of 34 patients with polymyalgia rheumatica (PMR) found that baricitinib, a Janus kinase inhibitor, effectively reduced symptoms without the use of oral glucocorticoids. At week 12, 78% of patients on baricitinib achieved a C-reactive protein PMR activity score of 10 or less, compared with 13% in the placebo group. The trial, named BACHELOR, highlights the potential for glucocorticoid-sparing treatments in PMR, addressing the need for alternatives due to the side effects and relapse rates associated with long-term steroid use. These findings emphasize the need for further research into steroid-sparing strategies for PMR, particularly for patients who are intolerant to steroids or have comorbidities that complicate steroid use. The study was funded by Eli Lilly and Centre Hospitalier Universitaire Brest.
The Takeaway:Baricitinib offers a steroid-free option for managing polymyalgia rheumatica.